Table 5.
Cost-effectiveness analysis: base-case scenario (rFIXFc once-weekly prophylaxis)
| rFIXFc prophylaxis | rFIX on-demand | Incremental | |
|---|---|---|---|
| Total costs, € | 5,308,625 | 6,564,510 | − 1,255,885 |
| Prophylaxis—drug | 4,715,315 | 0 | 4,715,315 |
| Bleeding management—drug | 323,730 | 3,820,085 | − 3,496,355 |
| Bleeding management—HCR | 229,888 | 2,418,138 | − 2,188,250 |
| Joint (hip/knee) surgery | 11,166 | 25,840 | − 14,674 |
| Indirect | 28,526 | 300,446 | − 271,920 |
| Total QALYs | 15.936 | 11.943 | 3.993 |
| QALYs in no bleeds state | 3.788 | 0 | 3.788 |
| QALYs in any bleeds state | 12.207 | 12.520 | − 0.314 |
| QALY loss due to bleed | 0.058 | 0.572 | − 0.514 |
| QALY loss due to surgery | 0.001 | 0.005 | − 0.004 |
| Total LYs | 22.91 | 22.91 | 0 |
| Number of bleeds | 71.48 | 753.77 | − 682.29 |
| Number of surgeries | 0.14 | 0.53 | − 0.39 |
| ICER (cost/QALY gained) | Dominant | ||
| ICER (cost/bleed avoided) | Dominant |
HCR healthcare resources, ICER incremental cost-effectiveness ratio, LY life year, QALY quality-adjusted life year, rFIX recombinant coagulation factor IX, rFIXFc recombinant coagulation factor IX Fc fusion protein